Pulmonary Fibrosis

Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases. Read More

Scientists at Vanderbilt University Medical Center and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF). Read More

Lung diseases of infancy and aging share a molecular signature, pointing to a potential target for treatment and prevention. Read More

To develop strategies for preventing radiation-induced lung fibrosis (scarring), Vanderbilt investigators are exploring the cell types and factors that contribute to the fibrotic response. Read More

New findings identify isoketal-modified proteins as a previously unrecognized feature of pulmonary fibrosis and as a potential therapeutic target for this disease. Read More

Vanderbilt University Medical Center is launching a research study for a rare disease called Hermansky-Pudlak Syndrome (HPS), an inherited disorder that causes albinism, decreased visual acuity and susceptibility to bleeding due to platelet dysfunction. Read More

Lisa Young, M.D., associate professor of Pediatrics and Medicine and Cell Biology, has been awarded a five-year, $1.9 million National Institutes of Health grant to study what causes cellular dysfunction and pulmonary fibrosis in patients with Hermansky-Pudlak syndrome (HPS). Read More

Targeting repair pathways in the lung’s air sacs may be a valuable therapeutic direction for pulmonary fibrosis – the scarring of lung tissue. Read More

A rare genetic syndrome provides new clues to lung scarring (pulmonary fibrosis), a potentially deadly consequence of many lung diseases. Read More